220 related articles for article (PubMed ID: 30726248)
41. Aerosolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury.
Hashimoto S; Wolfe E; Guglielmo B; Shanks R; Sundelof J; Pittet JF; Thomas E; Wiener-Kronish J
J Antimicrob Chemother; 1996 Nov; 38(5):809-18. PubMed ID: 8961050
[TBL] [Abstract][Full Text] [Related]
42. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
43. Antibacterial activity of imipenem: the first thienamycin antibiotic.
Kropp H; Gerckens L; Sundelof JG; Kahan FM
Rev Infect Dis; 1985; 7 Suppl 3():S389-410. PubMed ID: 3931196
[TBL] [Abstract][Full Text] [Related]
44. Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus.
Oka S; Goto M; Kaji Y; Kimura S; Matsuda K; Asahi Y; Sanada M; Nakagawa S; Inoue M; Shimada K
J Antimicrob Chemother; 1993 Apr; 31(4):533-41. PubMed ID: 8514648
[TBL] [Abstract][Full Text] [Related]
45. [Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections].
Naber KG; Adam D; Bauernfeind A; Hönig E
Infection; 1986; 14 Suppl 2():S122-9. PubMed ID: 2428754
[TBL] [Abstract][Full Text] [Related]
46. Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model.
Ernst EJ; Hashimoto S; Guglielmo J; Sawa T; Pittet JF; Kropp H; Jackson JJ; Wiener-Kronish JP
Antimicrob Agents Chemother; 1999 Oct; 43(10):2389-94. PubMed ID: 10508012
[TBL] [Abstract][Full Text] [Related]
47. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
Bauernfeind A; Jungwirth R; Schweighart S
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418
[TBL] [Abstract][Full Text] [Related]
48. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
Buckley MM; Brogden RN; Barradell LB; Goa KL
Drugs; 1992 Sep; 44(3):408-44. PubMed ID: 1382937
[TBL] [Abstract][Full Text] [Related]
49. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
[TBL] [Abstract][Full Text] [Related]
50. [Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
Hashira S; Tajima T; Fujii R
Jpn J Antibiot; 1989 May; 42(5):1077-86. PubMed ID: 2746857
[TBL] [Abstract][Full Text] [Related]
51. Thienamycin: development of imipenen-cilastatin.
Kahan FM; Kropp H; Sundelof JG; Birnbaum J
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():1-35. PubMed ID: 6365872
[TBL] [Abstract][Full Text] [Related]
52. Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model.
Zuluaga AF; Rodriguez CA; Agudelo M; Vesga O
BMC Res Notes; 2015 Oct; 8():546. PubMed ID: 26445936
[TBL] [Abstract][Full Text] [Related]
53. Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience.
Acar JF
Rev Infect Dis; 1985; 7 Suppl 3():S513-7. PubMed ID: 3931199
[TBL] [Abstract][Full Text] [Related]
54. [Clinical experience with imipenem/cilastatin in the treatment of severe infections in general surgery].
Mayer M; Brand J; Schlenkhoff D; Opferkuch W
Infection; 1986; 14 Suppl 2():S160-3. PubMed ID: 3079549
[TBL] [Abstract][Full Text] [Related]
55. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
Verwaest C;
Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
[TBL] [Abstract][Full Text] [Related]
56. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
57. [Clinical laboratory approach to estimating the effective administration dose of imipenem/cilastatin. Evaluation of the disk susceptibility test and its interpretation system].
Matsuo K; Uete T
Jpn J Antibiot; 1989 Nov; 42(11):2377-92. PubMed ID: 2621780
[TBL] [Abstract][Full Text] [Related]
58. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
[TBL] [Abstract][Full Text] [Related]
59. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
[TBL] [Abstract][Full Text] [Related]
60. Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia.
Kaneko Y; Yanagihara K; Kuroki M; Ohi H; Kakeya H; Miyazaki Y; Higashiyama Y; Hirakata Y; Tomono K; Kadota JI; Kohno S
Chemotherapy; 2001 Dec; 47(6):421-9. PubMed ID: 11786657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
